Wolfgang Miesbach/LinkedIn
Feb 25, 2026, 12:36
Wolfgang Miesbach: Repurposing Metformin – From Sugar Control to Thrombus Control
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared on LinkedIn:
”Repurposing Metformin: From Sugar Control to Thrombus Control
One of the many excellent posters at this year’s GTH 2026 meeting in Bonn was from the team in Düsseldorf, exploring an unexpected player in abdominal aortic aneurysm (AAA) therapy: the antidiabetic drug metformin.
Their work looks at how metformin modulates platelet activation and ex vivo thrombus formation in human whole blood – a fascinating angle, given the growing recognition that platelets and intraluminal thrombus are not just bystanders but active drivers of AAA progression:
- A ‘classic’ diabetes drug being repurposed to target vascular inflammation and thrombosis, in a disease area where truly effective pharmacological treatments are still lacking.
- Experimental data suggesting that metformin can inhibit platelet activation and arterial/venous thrombosis without prolonging bleeding time, by acting on mitochondrial pathways – hinting at a new, ‘metabolic’ form of antiplatelet therapy.
- Use of human samples and arterial‑shear thrombus assays keeps the model close to clinical reality and directly links cellular mechanisms to the thrombotic milieu observed in AAA.
- The concept that dampening platelet hyperreactivity might not only reduce thrombotic complications but also slow aneurysm expansion is particularly attractive and could complement ongoing clinical trials of metformin in AAA.”

Stay updated with Hemostasis Today.
-
Jul 14, 2026, 19:35Daratumumab in Difficult-to-Treat iTTP: Updated Results from the International DarTTP Study
-
Jul 14, 2026, 17:1610 Posts Not To Miss from ISTH 2026, Part 3
-
Jul 14, 2026, 15:27Dianne E Van Der Wal: Celebrating Scientific Contributions at ISTH 2026
-
Jul 14, 2026, 15:13Alfonso Tafur: RIETE Registry Analysis Supports More Equitable Approaches to VTE Care
-
Jul 14, 2026, 15:03Heghine Khachatryan: Phase III Trial Results Support BAFF-R Inhibition in Corticosteroid-Refractory ITP
-
Jul 14, 2026, 14:51Nathan Connell: ISTH 2026 Highlights the Power of Lifelong Collaboration
-
Jul 14, 2026, 14:42Wolfgang Miesbach: VOYAGER1 Highlights Progress Toward Injection-Free Care in Hemophilia A
-
Jul 14, 2026, 12:08Elvira Grandone: Finding the Right LMWH Dose for Pregnant Patients Suffering From DVT
-
Jul 14, 2026, 12:05Eloïse Laouenan: From Washington to Paris – Join GETBO at ISTH 2026